Callan Family Office LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Callan Family Office LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,887 shares of the medical research company’s stock after selling 2,147 shares during the period. Callan Family Office LLC’s holdings in Thermo Fisher Scientific were worth $5,915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $30,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at $35,000. Navigoe LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $462.59 on Tuesday. The business has a 50-day moving average of $428.13 and a 200 day moving average of $461.84. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a market capitalization of $174.68 billion, a price-to-earnings ratio of 26.75, a price-to-earnings-growth ratio of 2.46 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TMO shares. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday. HSBC reaffirmed a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Finally, Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $593.00.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock valued at $8,345,792 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.